Aktuellt
SENASTE
The company announced on 2 September that the 5–7-year follow-up data for the first trial with the Episealer system has been accepted for publication. We view this as important (even though it is a small trial) as it should validate the long-term outcome of Episealer treatment. We understand there have been no revisions for five years and the patients feel as well as after the 2-year follow-up. We reiterate our fair value of SEK2.7–8.2.
LÄS MER
